VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, December 31, 2025
Stock Comparison
Bristol-Myers Squibb Company vs Hermes International Societe en commandite par actions
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Bristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisHermes International Societe en commandite par actions
RMS · Euronext Paris
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Hermes International Societe en commandite par actions's moat claims, evidence, and risks.
View RMS analysisComparison highlights
- Moat score gap: Hermes International Societe en commandite par actions leads (79 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)); Hermes International Societe en commandite par actions has 7 segments (42.6% in Leather Goods and Saddlery).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Bristol-Myers Squibb Company has 4 moat types across 3 domains; Hermes International Societe en commandite par actions has 5 across 2.
Primary market context
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
Hermes International Societe en commandite par actions
Leather Goods and Saddlery
Ultra-premium leather goods and luxury handbags
Global
Affluent consumers
Brand owner, artisan manufacturer, direct retailer
42.6%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
Bristol-Myers Squibb Company strengths
Hermes International Societe en commandite par actions strengths
Segment mix
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
Hermes International Societe en commandite par actions segments
Full profile >Leather Goods and Saddlery
Oligopoly
Ready-to-wear and Accessories
Competitive
Silk and Textiles
Competitive
Other Hermes sectors (Jewelry, Home, etc.)
Competitive
Perfume and Beauty
Competitive
Watches
Competitive
Other products (Third-party production)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.